CUMBERLAND PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
About Cumberland Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Cumberland Pharmaceuticals Inc. is a specialty biopharmaceutical company that acquires, develops, and commercializes branded prescription pharmaceuticals. Its core business focuses on hospital acute care, gastroenterology, and oncology. The company's commercial portfolio includes Acetadote for acetaminophen toxicity, Caldolor for pain and fever, Kristalose for constipation, Sancuso for chemotherapy-induced nausea and vomiting, Vaprisol for hyponatremia, Vibativ for serious bacterial infections, and Talicia for Helicobacter pylori infections. Cumberland distributes its medicines primarily to wholesale pharmaceutical distributors in the United States, promoting its therapies to physicians, hospitals, clinics, and medical specialists through hospital, field, and oncology sales forces.
The company is headquartered in Nashville, Tennessee, and was incorporated within the state. Cumberland maintains a dedicated commercial team of approximately 60 sales professionals across the United States. Beyond its domestic operations, the business reaches global markets by licensing its pharmaceutical brands to regional partners across multiple international territories, including Australia, South Korea, China and Hong Kong, Mexico, Russia, Saudi Arabia, and Jordan.
Summary of the business section of Cumberland Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CUMBERLAND PHARMACEUTICALS INC
- Founded
- 1999
- Headquarters
- Nashville,, TN
- Address
- 1600 West End Avenue, Suite 1300 37203
- Phone
- (615) 255-0068
- Website
- cumberlandpharma.com
- Employees
- 93, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Tennessee
- Fiscal year ends
- December 31
- Auditor
- Carr, Riggs & Ingram, LLC, Nashville, Tennessee
Stock & identifiers
- Ticker
- CPIX
- Exchange
- Nasdaq
- Shares outstanding
- 15M, Aug 5, 2026
- Public float
- $29.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1087294
- CUSIP
- 230770109
- ISIN
- US2307701092
- EIN
- 62-1765329
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| A. J. Kazimi | Chairman and CEO, Director | 5,695,310 |
| James L. Herman | VP and Chief Compliance Office | 38,255 |
| John M. Hamm | VP Chief Financial Officer | 20,073 |
| Todd M. Anthony | Vice Pres Organizational Dev | 16,328 |
| Chris T. Bitterman | Vice Pres Sales & Marketing | 4,683 |
| Kenneth Krogulski | Director | 302,338 |
| James Jones | Director | 46,863 |
| Caroline Young | Director | 35,109 |
| Martin S. Brown JR | Director | 10,300 |
| Joseph C. Galante | Director | 63,656 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.24M | $979.85K | $341.19K | $135 | $132 |
| FY2024 | $1.11M | $979.27K | $315.61K | $46 | $62 |
| FY2023 | $979.68K | $952.53K | $326.89K | $35 | $43 |
| FY2022 | $583.44K | $897.50K | $305.57K | $44 | $49 |
| FY2021 | $1.53M | $872.63K | $411.78K | $91 | $72 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 93 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 1, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 26, 2026 | Merger vote | Definitive merger proxy statement |
| Jun 2, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 24, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 6, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 1, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 3, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 16, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 22, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 16, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 1, 2007 | Listing | Registration of securities on an exchange (Form 8-A) |